Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics to $86 from $80 and keeps a Buy rating on the shares. The analyst moving up assumptions around the timing of when the company will file a supplemental new drug application for lead asset AXS-05 in the setting of Alzheimer’s disease agitation and increased the probability of success for AXS-05 in this setting to 75% from 65%. The move is based on positive feedback from a key opinion leader who has prior experience working with the FDA, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics initiated with a Neutral at Piper Sandler
- Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
- Axsome Therapeutics price target raised to $98 from $62 at BTIG
- AXSOME call volume above normal and directionally bullish
- Axsome Therapeutics presents data on EVOLVE open-label trial of AUVELITY